Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00478179 | Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia | PHASE2 | COMPLETED | 60 | — | — | Sep 1, 2006 | Dec 1, 2007 | Sep 11, 2009 | 7 | United States |
| Name | Type | Description |
|---|---|---|
| Transdermal/Patch (Bupivacaine TTS [Eladur™]) | DRUG | - |
Inclusion Criteria: * Male or females age 21 years or older. * Pain in thoracic or lumbar regions for a minimum of 90 days after crusting of Herpes Zoster (HZ) lesions. * Stable prescribed medications regimen (including opioids, anticonvulsants, and tricyclic antidepressants). * Intact, unbroken sk...